Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31736930 | 0.80 | TAAR1 (0.55) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL11152261 | 0.78 | TAAR1 (0.59) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL933385 | 0.76 | TAAR1 (0.50) | TAAR1IDO1MAOBCYP11B1CYP11B2 | |
| SCHEMBL1538033 | 0.76 | TAAR1 (0.50) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL1001014 | 0.76 | PNMT (0.54) | TAAR1IDO1AGXTMAOB | |
| SCHEMBL9200966 | 0.75 | TAAR1 (0.60) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL4399626 | 0.75 | TAAR1 (0.74) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL11149029 | 0.75 | TAAR1 (0.55) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL29353789 | 0.73 | — | — | |
| SCHEMBL6882 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | claimed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | claimed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| US-20260132149-A1 | Bridged Cyclic 5-Amino-6,8-Dihydro-1H-Furo[3,4-D]Pyrrolo[3,2-B]Pyridine-2-Carboxamide Compounds, Compositions Thereof, and Methods of Treatment Therewith | BEONE MEDICINES I GMBH (CH) | 2026-05-14 | — | — | US | disclosed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11634449-B2 | Macrolides and methods of their preparation and use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-04-25 | — | — | US | disclosed |
| EP-4095146-A1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | President And Fellows Of Harvard College (US) | 2022-11-30 | — | — | EP | disclosed |
| US-20220332747-A1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-10-20 | — | — | US | disclosed |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2002-05-30 | — | — | US | disclosed |
| WO-2002042268-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O'KEEFE (US) | 2002-04-04 | — | — | US | disclosed |
| WO-2002016393-A1 | 17-ARYL-LINKER DERIVATISED ESTROGEN 3-SULPHAMATES AS INHIBITORS OF STEROID SULPHATASE | STERIX LIMITED (GB) | 2002-02-28 | — | — | WO | disclosed |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PRODUCTS INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001046140-A1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1110949-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | TAAR1 319/4885IDO1 1289/4885AGXT 3804/4885 |
| US-20220332747-A1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | CYP11B2, ERG28, DHCR7 | TAAR1 4465/4885IDO1 3560/4885AGXT 1251/4885 |
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | TAAR1 1909/4885IDO1 417/4885AGXT 4349/4885 |
| US-11634449-B2 | Macrolides and methods of their preparation and use | CYP11B2, ERG28, DHCR7 | TAAR1 4465/4885IDO1 3560/4885AGXT 1251/4885 |
| US-20260132149-A1 | Bridged Cyclic 5-Amino-6,8-Dihydro-1H-Furo[3,4-D]Pyrrolo[3,2-B]Pyridine-2-Carboxamide Compounds, Compositions Thereof, and Methods of Treatment Therewith | MECP2, PRMT5, DNMT1 | TAAR1 3730/4885IDO1 3024/4885AGXT 3877/4885 |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | TAAR1 1736/4885IDO1 591/4885AGXT 4390/4885 |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | TAAR1 1909/4885IDO1 417/4885AGXT 4349/4885 |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | NR3C2, MGLL, GCG | TAAR1 3193/4885IDO1 4697/4885AGXT 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.